Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?

Neuro-Oncology · Published 2026-05-20 · DOI 10.1093/neuonc/noag117

Free full text

Authors (10)

Mustafa Khasraw, Matthew D Dun, Isabel Arrillaga-Romany, Roel G W Verhaak, Eric Bouffet, Jordan R Hansford, Kirit Singh, Sabine Mueller, Carl Koschmann, Patrick Y. Wen

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Khasraw, M., Dun, M., Arrillaga-Romany, I., et al. (2026). Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag117

Related articles